重组人类基因促红细胞生成素在治疗早产儿脑损伤中的应用

Application of Recombinant Human Erythropoietin in the Treatment of Premature Infant Brain Injury

本研究将78例脑损伤早产儿根据随机数字表分为两组,其中对照组予以常规治疗,观察组予以重组人类基因促红细胞生成素治疗。对比两组治疗前后的NBNA、MDI、PDI评分,NSE、S-100B、BUN、Cr、SGPT、TBIL的水平变化,发现两组纠正胎龄40周时的NBNA评分较治疗前明显改善,且观察组的改善程度较对照组明显(p<0.05)。两组在纠正胎龄3个月及6个月的MDI及PDI得分差异有统计学意义,观察组的改善程度较对照组明显,差异有统计学意义(p<0.05)。两组治疗后的NSE和S-100B水平较治疗前降低,且观察组比对照组降低明显(p<0.05)。两组治疗前后血清BUN、Cr、SGPT、TBIL水平差异无统计学意义(p>0.05)。提示rhEPO对受损脑细胞有保护作用,可在一定程度上促进神经系统的修复,在改善早产儿脑损伤预后方面有着积极的作用。

In this study, 78 premature infants with brain injury were divided into two groups according to the random number table. Control group was treated by conventional therapy while observation group was treated by rhEPO. After contrasting the NBNA scores, MDI scores, PDI scores, NSE, S-100B, BUN, Cr, SGPT, TBIL levels change before and after treatment, we found that the NBNA scores of correct gestational age at 40 weeks of the two groups were obviously better than those before treatment and the change of the observation group was more obvious than the control group （p〈0.05）. The differences between the two groups of MDI scores and PDI scores at correct gestational age at 3 and 6 months were statistically significant, and the change of the observation group was more obvious than the control group, and the difference was statistically significant （p 〈0.05）; The levels of NSE and S-100B of two groups after treatment were lower than those before treatment and the change of the observation group was more obvious than the control group （p〈0.05）. However, there were no significant differences of serum BUN, Cr, SGPT, and TBIL levels before and after treatment （p〉0.05）. In conclusion, rhEPO could protect damaged brain cells, which could promote the repair of nervous system injury to a certain extent, and had a positive effect on improving the prognosis of brain injury in premature infants.